vimarsana.com

Page 10 - நீண்டது கால பராமரிப்பு ப்ரோக்ர்யாம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

CVS Health Surpasses 10 Million COVID-19 Vaccine Doses Administered

Share this article Share this article WOONSOCKET, R.I., April 1, 2021 /PRNewswire/ CVS Health (NYSE: CVS) has surpassed 10 million COVID-19 vaccine doses administered through its participation in the Pharmacy Partnership for Long-Term Care Program and Federal Retail Pharmacy Program. The company is now administering vaccines in nearly 2,000 stores across 44 states, Puerto Rico, and Washington, D.C., with the pace of vaccinations expected to rapidly accelerate as more supply becomes available. CVS Pharmacy has the capacity to administer up to 25 million shots per month. We ve experienced some of our highest customer satisfaction scores ever, which speaks to the seamless digital scheduling experience we ve built and the professionalism of our health care teams putting shots in arms, said Karen S. Lynch, President and Chief Executive Officer, CVS Health. We re working hard to help America fight COVID-19 by breaking down barriers to equitable health care, especially in communiti

Evaluation of Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities

Evaluation of Pfizer-BioNTech COVID-19 vaccine among residents of two skilled nursing facilities The severity of COVID-19 among the residents of long-term care facilities (LTCFs) has been reported to be disproportionately high. Specifically, individuals residing in skilled nursing facilities (SNFs) are found to be the most severely affected, both in terms of morbidity and mortality, and are, thereby, listed for early COVID-19 vaccination. In comparison to the general population, SNF residents are more vulnerable, with a weak immune system. LTCFs and SNFs were not included in the clinical trials of COVID-19 vaccines. This resulted in a limitation, i.e., minimal data to determine the vaccine effectiveness (VE) for this vulnerable group. Additionally, in the case of the Pfizer-BioNTech vaccine, the immunogenicity was found to be lower in the age group between 65–85 years. However, for the younger population, the vaccine was found to be more efficient.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.